EOS-215 / iTeos - LARVOL DELTA

A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=3 | Terminated | Sponsor: iTeos Belgium SA | N=94 ➔ 3 | Trial completion date: May 2027 ➔ Jul 2025 | Active, not recruiting ➔ Terminated | Trial primary completion date: Apr 2027 ➔ Jul 2025; The study was terminated early due to sponsor's strategic business decision.

Enrollment change • Monotherapy • Trial completion date • Trial primary completion date • Trial termination • Oncology • Solid Tumor

A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=94 | Active, not recruiting | Sponsor: iTeos Belgium SA | Recruiting ➔ Active, not recruiting

Enrollment closed • Oncology • Solid Tumor

iTeos Therapeutics Announces Its Intention to Wind Down Operations (GlobeNewswire) - "Following a thorough assessment of the Company’s development pipeline, business prospects, and financial position, the Company’s Board of Directors intends to wind down clinical and operational activities and focus on leveraging the Company’s cash balance to deliver near-term value to shareholders, including any proceeds from the potential sale of the Company’s intellectual property and assets such as EOS-984, EOS-215, and a preclinical obesity program targeting ENT1." "

Commercial • Oncology

EOS-215, a first-in-class TREM2 antagonist, designed to reprogram the tumor microenvironment and overcome resistance (AACR 2025) - "In conclusion, EOS-215 is a potent TREM2 antagonist with a sub-nM potency proven preclinically to block pro-tumoral function in macrophages, consequently leading to in vivo efficacy. EOS-215 is now ready to enter clinical trials in 2025."

Biomarker • IO biomarker • Tumor microenvironment • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=94 | Recruiting | Sponsor: iTeos Belgium SA | Not yet recruiting ➔ Recruiting

Enrollment open • Monotherapy • Oncology • Solid Tumor

iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025 (GlobeNewswire) - "iTeos Therapeutics...announced the poster presentations of preclinical data on EOS-215, a potential best-in-class antibody targeting TREM2, and a novel small molecule inhibiting PTPN1/2 at the American Association for Cancer Research (AACR) Annual Meeting..."

Preclinical • Solid Tumor

iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire) - "TIG-006 HNSCC: Topline data from the TIG-006 study in cohorts 2C & 2D assessing belrestotug + dostarlimab doublet in first-line PD-L1 positive advanced / metastatic HNSCC anticipated in 2025 to include safety, ORR, and PFS from a total of 42 patients....TRM-010: Investigative New Drug (IND) application was submitted and allowed to proceed for a Phase 1 of EOS-215. Patient enrollment is anticipated in 2Q25."

IND • New P1 trial • P1/2 data • Squamous Cell Carcinoma of Head and Neck

iTeos Announces 2025 Strategic Priorities and Anticipated Milestones (GlobeNewswire) - "APT-008: Topline data assessing EOS-984 as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors anticipated in 2H25....TRM-010: Investigative New Drug (IND) application for EOS-215 anticipated in 1Q25."

IND • P1 data • Oncology • Solid Tumor